Abstract
ACE inhibitors have become an essential component in the treatment of heart failure. But is low-dose ACE inhibitor therapy as effective as high-dose ACE inhibitor therapy in this indication? This question was addressed at the 47th Annual Scientific Sessions of the American College of Cardiology [Atlanta, US; March 1998], where the results of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial were presented.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
